GlassScriptPhysician profile
Lloyd G Geddes
NPI 1730193046
$2,835.58
in general payments reported to CMS, 2019-2025
16 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $126 · 2021: $162 · 2022: $163 · 2024: $1,820 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,104 · Food and Beverage: $834 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,103.51 |
| Food and Beverage | $833.58 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,722.04 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $173.57 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $150.00 | 2024 | Monoferric |
| Amgen INC. | $139.98 | 2019-2021 | |
| Janssen Biotech, INC. | $132.77 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $111.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $89.22 | 2021 | |
| Agios Pharmaceuticals, INC. | $82.40 | 2024 | Pyrukynd |
| Genentech USA, INC. | $69.18 | 2019 | |
| Pfizer INC. | $38.31 | 2019 | |
| Lilly USA, LLC | $37.82 | 2019 | |
| Immunocore Limited | $28.52 | 2022 | |
| Incyte Corporation | $20.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.67 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Geddes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.